EU rights and policies

This subtopic concerns matters relating to EU social and economic rights and policies, including the four freedoms underpinning the EU Internal Market:

  1. free movement of goods

  2. freedom of establishment and to provide services

  3. free movement of capital

  4. free movement of persons

Freedom of establishment and to provide services are closely related and can be regarded as, in effect, one ‘freedom’.

Social rights

Most social and employment legislation in the EU is the responsibility of individual Member States, but certain aspects of employment and social protection are affected by EU legislation. There would be no economic and social cohesion without a legal framework to ensure fair treatment for all citizens, and to ensure that businesses are not incentivised to move to areas where labour is cheaper. However, social policy is closely linked to the political ethos of national governments, so increasing competence at the EU level creates tension with Member States.

Although social policy is a shared competence, this competence has been increasingly exercised by EU institutions while stopping short of harmonising laws across the EU. Embedded into the aims

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

Commission publishes updated clinical trials guidance package

The European Commission's Directorate-General for Health and Food Safety has published a comprehensive package of updated clinical trials guidance documents, all endorsed by the Clinical Trials Coordination and Advisory Group (CTAG) on 15 October 2025. The package includes new recommendations on criteria for selecting a reporting Member State under Article 85(2)(c) of the Clinical Trials Regulation, establishing a workshare criterion when proposed reporting Member States decline the role, which occurs in approximately 30% of applications. The Commission has updated its recommendation paper on decentralised elements in clinical trials (Version 02), superseding the December 2022 version, with revised national provision overviews and guidance on informed consent, investigational medicinal product delivery, and remote monitoring. A new recommendation paper addresses frequent issues identified during Part I and Part II assessments, based on feedback from national competent authorities and ethics committees, covering investigational medicinal product dossiers, protocols, and safety reporting. The package also includes revised guidance on auxiliary medicinal products, effective 1 December 2025 for new applications, featuring an updated classification system distinguishing between authorised, modified authorised, and unauthorised auxiliary medicinal products with corresponding application and safety reporting requirements.

View EU Law by content type :

Popular documents